Understand the source comparison
Peptides for IBS-C: Research Protocol Comparison
BPC-157 Nitric oxide pathway modulation; promotes smooth muscle relaxation and mucosal healing 250–500mcg per dose, 1–2× daily Subcutaneous or oral Preclinical rodent models strong; human case series limited, no RCTs Most studied peptide for gut motility. Mech
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Nitric oxide pathway modulation; promotes smooth muscle relaxation and mucosal healing
- 250–500mcg per dose, 1–2× daily
- Subcutaneous or oral
- Preclinical rodent models strong; human case series limited, no RCTs
- Most studied peptide for gut motility. Mechanistic plausibility high, human efficacy data weak
- KPV (Lys-Pro-Val)
- NF-kB inhibition; reduces inflammatory cytokine expression in intestinal mucosa
- 500–1000mcg per dose, 1× daily
- Preclinical IBD models strong; Phase I safety trial completed, no efficacy trials in IBS-C
- Anti-inflammatory mechanism relevant to IBS-C, but evidence is extrapolated from IBD research
- Thymosin Beta-4
- Promotes epithelial migration and tight junction repair; reduces intestinal permeability
- 2–5mg per dose, 2–3× weekly
- Subcutaneous
- Preclinical wound healing models only; no published IBS-C studies
- Barrier repair mechanism theoretically relevant, but zero direct IBS-C evidence
- Semax
- Modulates BDNF (brain-derived neurotrophic factor) and gut-brain axis signaling
- 300–600mcg intranasal, 1× daily
- Intranasal
- Preclinical neuroprotection models; gut-brain axis effects inferred, not demonstrated
- Gut-brain modulation is compelling in theory. Lacks direct motility or inflammation data